Clinical Trials Browser

Phase 2 × INDUSTRY × sotigalimab × Clear all

NCT03165994 2024-05-02

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Phase 2 Completed

34 enrolled 18 charts

Gastrointestinal

Esophageal Neoplasms

NCT04337931 2024-02-13

A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma

Phase 2 Terminated

45 enrolled 14 charts

Melanoma, Neoplasms, Skin Neoplasms